Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab (IBI306) in Chinese Non-familial Hypercholesterolemia (CREDIT-1)
NCT04289285Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Apr 2020
- Primary completion
- Feb 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafolecimab in hypercholesterolemia (4 arms), sponsored by Innovent Biologics. Primary endpoint: Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 48. Started Apr 2020; status: completed.
02
Drugs
tafolecimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04289285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04289285.